Quick Answer
Travere Therapeutics, Inc. reported Cash And Cash Equivalents At Carrying Value of $93.04 million for the year ending 2025.
- Travere Therapeutics, Inc. showed an increase of +58.9% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from Travere Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 19, 2026.
- XBRL data for this metric is available from 2011 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 15 years of available data (2011 to 2025), Travere Therapeutics, Inc.'s Cash And Cash Equivalents At Carrying Value has grown by 925,345.1%.
- Historical annual values: Fiscal year 2025: $93.04 million | Fiscal year 2024: $58.54 million | Fiscal year 2023: $58.18 million | Fiscal year 2022: $61.69 million | Fiscal year 2021: $165.75 million | Fiscal year 2020: $84.77 million | Fiscal year 2019: $62.44 million | Fiscal year 2018: $102.87 million | Fiscal year 2017: $99.39 million | Fiscal year 2016: $41.00 million | Fiscal year 2015: $37.81 million | Fiscal year 2014: $18.20 million | Fiscal year 2013: $6.00 million | Fiscal year 2012: $11.0 thousand | Fiscal year 2011: $10.1 thousand.
- Data sourced from SEC EDGAR public filings as of June 23, 2026.
Last verified: